NVX-COV2373
Highest phase reached
Phase 3
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Protein
- Drug name
- NVX-COV2373
- covovax vaccine protein antigen
- Covovax vaccine protein antigen
- nvx cov 2372
- nvx cov2373
- Nvx-cov 2372
- Nvx-cov2373
- NVX-Cov2373
- NVX-CoV2373
- NVX-CoV2373 (5μg)
- sars cov 2 spike glycoprotein vaccine antigen nvx cov2373
- SARS-COV-2 SPIKE GLYCOPROTEIN VACCINE ANTIGEN NVX-COV2373
- tak 019
- TAK-019
- CAS registry numbers
- 2972498-09-0
- ChEMBL ID
- CHEMBL5095387
- RxNorm IDs (RxCUI)
- 2606073
- FDA ingredient codes (UNII)
- UK9AK2IN1P
- First in class
- No
- Orphan designation
- No
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000694
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT04712110
- NCT05112848
- NCT05249816
- NCT05299359
- NCT05372588
- NCT05463068
- NCT05775887
- NCT05875701
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
Related records
Trials (11)
- A FIRST IN HUMAN TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF SARS-CoV-2 UQSC2 VACCINE IN HEALTHY ADULTS.
- A proof-of Concept, Randomized 3-month Study to Evaluate the Effects of Three Contraceptive Intrauterine Systems Delivering Copper and a Daily Dose of 5, 20 or 40 μg of Ulipristal Acetate (UPA)
- A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)
- A Study of TAK-019 in Healthy Japanese Adults (COVID-19)
- A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)
- COVID-19 Vaccines Safety Tracking (CoVaST)
- Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
- Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine
- Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines
- Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
- Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
In development for (2)
- COVID-19 Phase 3
- Severe acute respiratory syndrome Phase 3